去铁铁治疗β -地中海贫血期间的视觉和听觉并发症

Parastoo Poosheshdoost, N. Faraji, Tahereh Zeinali, A. Baghersalimi, Aye Miremarati, B. Darbandi
{"title":"去铁铁治疗β -地中海贫血期间的视觉和听觉并发症","authors":"Parastoo Poosheshdoost, N. Faraji, Tahereh Zeinali, A. Baghersalimi, Aye Miremarati, B. Darbandi","doi":"10.18502/ijpho.v12i4.10913","DOIUrl":null,"url":null,"abstract":"Background:  Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. \nMaterials and Methods: This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron chelator consumption admitted to the 17 Shahrivar Hospital and the Besat Clinic in Rasht, Iran. All the patients were examined for visual and auditory complications caused by deferasirox in 2019. A checklist of the patients' demographical and clinical data was recorded. Data analysis was done with SPSS and reported by descriptive statistics. Then, Fisher's exact test was performed to examine the association between visual and auditory disorders and the use of deferasirox in terms of disease-related variables including age, sex, age of onset of using chelator, drug use duration, drug dosage, and mean 6-months serum ferritin levels (P <0.05 as the significance level). \nResults:  Of a total of 156 patients, 103 (66%) were female and 56 (35.9%) were 20-30 years of age. The prevalence of visual acuity change was 0.6%, and the prevalence of sensorineural hearing loss was 1.3%. There was only one female with the visual disorder decreasing to 9/10 and with a dose of 31-40 mg/kg/day with an average of 1000-2500 ng/ml six-month ferritin. Also, two females with hearing impairment were confirmed with a dose of ≤30 mg/kg/day, and an average of ≤1000 ng/ml six-month ferritin. The Fisher's exact test results showed no significant relationship between visual and auditory disorders with the use of deferasirox in terms of disease-related variables (p>0.05). \nConclusion: The study's findings showed no significant relationship between visual and auditory disorders with deferasirox consumption. The results indicated the safety of deferasirox regarding visual and auditory side effects. More studies are required to confirm the findings.","PeriodicalId":129489,"journal":{"name":"Iranian Journal of Pediatric Hematology &amp; Oncology","volume":"3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia\",\"authors\":\"Parastoo Poosheshdoost, N. Faraji, Tahereh Zeinali, A. Baghersalimi, Aye Miremarati, B. Darbandi\",\"doi\":\"10.18502/ijpho.v12i4.10913\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background:  Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. \\nMaterials and Methods: This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron chelator consumption admitted to the 17 Shahrivar Hospital and the Besat Clinic in Rasht, Iran. All the patients were examined for visual and auditory complications caused by deferasirox in 2019. A checklist of the patients' demographical and clinical data was recorded. Data analysis was done with SPSS and reported by descriptive statistics. Then, Fisher's exact test was performed to examine the association between visual and auditory disorders and the use of deferasirox in terms of disease-related variables including age, sex, age of onset of using chelator, drug use duration, drug dosage, and mean 6-months serum ferritin levels (P <0.05 as the significance level). \\nResults:  Of a total of 156 patients, 103 (66%) were female and 56 (35.9%) were 20-30 years of age. The prevalence of visual acuity change was 0.6%, and the prevalence of sensorineural hearing loss was 1.3%. There was only one female with the visual disorder decreasing to 9/10 and with a dose of 31-40 mg/kg/day with an average of 1000-2500 ng/ml six-month ferritin. Also, two females with hearing impairment were confirmed with a dose of ≤30 mg/kg/day, and an average of ≤1000 ng/ml six-month ferritin. The Fisher's exact test results showed no significant relationship between visual and auditory disorders with the use of deferasirox in terms of disease-related variables (p>0.05). \\nConclusion: The study's findings showed no significant relationship between visual and auditory disorders with deferasirox consumption. The results indicated the safety of deferasirox regarding visual and auditory side effects. More studies are required to confirm the findings.\",\"PeriodicalId\":129489,\"journal\":{\"name\":\"Iranian Journal of Pediatric Hematology &amp; Oncology\",\"volume\":\"3 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Pediatric Hematology &amp; Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijpho.v12i4.10913\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pediatric Hematology &amp; Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijpho.v12i4.10913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:去铁铁是一种口服铁螯合剂,广泛用于治疗输血依赖性β-地中海贫血患者铁超载。本研究调查了去铁锈引起的视觉和听觉并发症的发生率。材料和方法:本横断面研究纳入了伊朗拉什特17 Shahrivar医院和Besat诊所收治的156例年龄小于18岁的输血依赖型β-地中海贫血和铁铁螯合剂消耗患者。2019年对所有患者进行去铁霉素所致的视觉和听觉并发症检查。记录了患者的人口统计和临床数据清单。数据分析采用SPSS统计软件,报告采用描述性统计方法。然后,采用Fisher精确检验,根据疾病相关变量,包括年龄、性别、开始使用螯合剂的年龄、用药持续时间、药物剂量和平均6个月血清铁蛋白水平,检验视觉和听觉障碍与去铁铁素使用之间的关系(P < 0.05)。结论:研究结果显示,视觉和听觉障碍与去铁酸铁摄入之间没有显著的关系。结果表明,在视觉和听觉方面,去铁宁是安全的。需要更多的研究来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia
Background:  Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. Materials and Methods: This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron chelator consumption admitted to the 17 Shahrivar Hospital and the Besat Clinic in Rasht, Iran. All the patients were examined for visual and auditory complications caused by deferasirox in 2019. A checklist of the patients' demographical and clinical data was recorded. Data analysis was done with SPSS and reported by descriptive statistics. Then, Fisher's exact test was performed to examine the association between visual and auditory disorders and the use of deferasirox in terms of disease-related variables including age, sex, age of onset of using chelator, drug use duration, drug dosage, and mean 6-months serum ferritin levels (P <0.05 as the significance level). Results:  Of a total of 156 patients, 103 (66%) were female and 56 (35.9%) were 20-30 years of age. The prevalence of visual acuity change was 0.6%, and the prevalence of sensorineural hearing loss was 1.3%. There was only one female with the visual disorder decreasing to 9/10 and with a dose of 31-40 mg/kg/day with an average of 1000-2500 ng/ml six-month ferritin. Also, two females with hearing impairment were confirmed with a dose of ≤30 mg/kg/day, and an average of ≤1000 ng/ml six-month ferritin. The Fisher's exact test results showed no significant relationship between visual and auditory disorders with the use of deferasirox in terms of disease-related variables (p>0.05). Conclusion: The study's findings showed no significant relationship between visual and auditory disorders with deferasirox consumption. The results indicated the safety of deferasirox regarding visual and auditory side effects. More studies are required to confirm the findings.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信